降脂药物的合理应用与药物性肝损伤

doi:10.3969/j.issn.1672-5069.2017.02.004

实用肝脏病杂志 ›› 2017, Vol. 20 ›› Issue (2): 139-141.doi: 10.3969/j.issn.1672-5069.2017.02.004

降脂药物的合理应用与药物性肝损伤

郑凯，李海

300162 天津市武警后勤学院附属医院肝胆胰脾科

收稿日期:2017-01-03 出版日期:2017-04-10 发布日期:2017-06-07
通讯作者: 李海，E-mail：15202265600@163.com
作者简介:郑凯，男，29岁，医师，硕士研究生。E-mail:13072003512@163.com

Hepatotoxicity of lipid-lowering agents

Zheng Kai，Li Hai.

Department of Hepatopancreatobiliary and Splenic Medicine，Affiliated Hospital， Logistical College of Chinese People's Armed Police Force，Tianjin 300162，China

Received:2017-01-03 Online:2017-04-10 Published:2017-06-07

摘要/Abstract

关键词: 药物性肝损伤, 降脂药物, 合理用药

Key words: Drug-induced liver injury, Lipid-lowering agents

郑凯，李海. 降脂药物的合理应用与药物性肝损伤[J]. 实用肝脏病杂志, 2017, 20(2): 139-141.

Zheng Kai，Li Hai.. Hepatotoxicity of lipid-lowering agents[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 139-141.

[1] Bjornsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int，2016[ahead of print].
[2] 范建高，颜士岩. 代谢综合征与脂肪肝. 临床肝胆病杂志，2016，32（3）:407-410.
[3] 范建高，潘勤. 加强高脂血症脂肪肝的基础和临床研究. 实用肝脏病杂志，2011，14（4）:241-242.
[4] Desai CS，Martin SS，Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ，2014，349:g3743.
[5] 傅青春. 药物性肝损伤诊断的因果评分系统. 实用肝脏病杂志，2014，17（6）:569-571.
[6] Demyen M，Alkhalloufi K，Pyrsopoulos NT. Lipid-lowering agents and hepatotoxicity. Clin Liver Dis，2013，17（4）:699-714.
[7] Tolosa L，Carmona A，Castell JV，et al. High-content screening of drug-induced mitochondrial impairment in hepatic cells:effects of statins. Arch Toxicol，2015，89（10）:1847-1860.
[8] Abdoli N，Heidari R，Azarmi Y，et al. Mechanisms of the statins cytotoxicity in freshly isolated rat hepatocytes. J Biochem Mol Toxicol，2013，27（6）:287-294.
[9] Szabo M，Veres Z，Batai-Konczos A，et al. Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes. Toxicol In Vitro，2014，28（6）:1136-1143.
[10] Chang CH，Chang YC，Lee YC，et al. Severe hepatic injury associated with different statins in patients with chronic liver disease:a nationwide population-based cohort study. J Gastroenterol Hepatol，2015，30（1）:155-162.
[11] Perdices EV，Medina-Caliz I，Hernando S，et al. Hepatotoxicity associated with statin use:analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev Esp Enferm Dig，2014，106（4）:246-254.
[12] Habib S，Shaikh OS. Drug-induced acute liver failure. Clin Liver Dis，2017，21（1）:151-162.
[13] Kubatka P，Kruzliak P，Rotrekl V，et al. Statins in oncological research:from experimental studies to clinical practice. Crit Rev Oncol Hematol，2014，92（3）:296-311.
[14] 范建高，蔡晓波. 他汀类药物肝脏安全性问题. 中华心血管病杂志，2007，21（6）:589-592.
[15] Younoszai Z，Li Z，Stepanova M，et al. Statin use is not associated with liver related mortality. Ann Hepatol，2013，13（1）:84-90.
[16] Lewis JH，Mortensen ME，Zweig S，et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective，randomized，double-blind，placebo-controlled，multicenter trial. Hepatology，2007，46（5）:1453-1463.
[17] Onofrei MD，Butler KL，Fuke DC，et al. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy，2008，28（4）:522-529.
[18] Abraldes JG，Albillos A，Banares R，et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension:a randomized controlled trial. Gastroenterology，2009，136（5）:1651-1658.
[19] Pollo-Flores P，Soldan M，Santos UC，et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis:A randomized controlled trial. Dig Liver Dis，2015，47（11）:957-963.
[20] 范建高，李光明. 他汀类药物在慢性肝病中的应用. 传染病信息，2011，22（5）:261-266.
[21] Chatrath H，Vuppalanchi R，Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis，2012，32（1）:22-29.
[22] Sarges P，Steinberg JM，Lewis JH. Drug-Induced Liver Injury: Highlights from a review of the 2015 literature. Drug Saf，2016，39（9）:801-821.
[23] 钟碧慧. 降脂药物在NAFLD患者中的合理应用. 实用肝脏病杂志，2016，19（2）:143-146.
[24] Russo MW，Hoofnagle JH，Gu J，et al. Spectrum of statin hepatotoxicity:experience of the drug-induced liver injury network. Hepatology，2014，60（2）:679-686.

降脂药物的合理应用与药物性肝损伤

Hepatotoxicity of lipid-lowering agents

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴欣, 郭杨志, 杜霄壤, 吴孟晋, 朱云, 冯兴中. 75例中药诱导的肝损伤患者临床特征分析*[J]. 实用肝脏病杂志, 2019, 22(5): 668-671.
[2]	刘立伟,赵新颜. 药物性肝损伤临床与组织病理学特点[J]. 实用肝脏病杂志, 2019, 22(2): 160-163.
[3]	黄春洋,单晶,廖慧钰,黄云丽,韩莹,张小丹,杜晓菲,任美欣,边新渠,刘燕敏. 甲基强的松龙治疗药物性肝损伤患者临床及实验室特点分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 208-211.
[4]	吴秀欣,张惠勇,张凯. 抗结核药物所致肝损伤患者血浆MiRNA-4284水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 212-215.
[5]	宋芳娇,朱冰,吕飒,田华,王海波,辛绍杰,游绍莉. 314例药物性肝衰竭患者临床特征分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 216-219.
[6]	孙文静, 陈东风. UCAM和Maria诊断标准用于评估1352例中国人药物性肝损伤文献分析[J]. 实用肝脏病杂志, 2018, 21(6): 881-884.
[7]	佟欣, 樊华. 双环醇治疗胃癌化疗所致肝损伤患者肝功能指标的变化[J]. 实用肝脏病杂志, 2018, 21(4): 625-626.
[8]	刘聪, 王婷婷, 左莉莉, 甄萍. 近3年住院患者药物性肝损伤状况调查[J]. 实用肝脏病杂志, 2018, 21(4): 639-640.
[9]	刘靓懿, 宿冬远. 药物性肝损伤与自身免疫性肝炎临床和肝组织病理学特征比较研究[J]. 实用肝脏病杂志, 2018, 21(3): 463-464.
[10]	陈杰, 范作鹏, 梁珊, 聂巍, 仇丽霞, 杨海霞, 林伟, 刘义荣, 张晶, 胡中杰. 合并慢性胆汁淤积性肝病对慢性药物性肝损害患者临床表现及对治疗应答的影响*[J]. 实用肝脏病杂志, 2017, 20(6): 720-723.
[11]	阮圣霆，夏光云. 异甘草酸镁与还原型谷胱甘肽治疗抗类风湿药物诱发的药物性肝损伤患者疗效比较[J]. 实用肝脏病杂志, 2017, 20(5): 608-609.
[12]	魏路佳, 李庆祥, 吉庆伟. 静脉用胺碘酮引起急性肝损害患者原因及其临床特点分析[J]. 实用肝脏病杂志, 2017, 20(4): 424-426.
[13]	张岱，王炳元. 重视损肝药物的新成员[J]. 实用肝脏病杂志, 2017, 20(2): 129-131.
[14]	王玉霞，都健. 256抗甲状腺药物肝损伤临床诊治进展[J]. 实用肝脏病杂志, 2017, 20(2): 135-138.
[15]	刘本，侯秋月. 阿拓莫兰对成人急性髓样白血病化疗患者肝功能损伤的预防作用观察[J]. 实用肝脏病杂志, 2016, 19(6): 717-719.